FAIR Obstacles for Curating SARS-CoV-2M-Protease Inhibitors
Description
Presented at BioIT World Europe, Berlin, October 2022
Despite COVID-19 vaccine successes there is an urgent need for small-molecule antivirals such as the recent Pfizer M-protease (M-prot) inhibitor nirmatrelvir, PF-07321332 exemplified in PMID34726479 and WO2021250648. Since 2020 the Guide to Pharmacology and BindingDB have collaborated on curating FAIR database entries for clinical candidate M-Prot inhibitors from papers and patents. Patterns of FAIR disclosure are patchy varying from open science data from the COVID Moon-shot consortium, a paper (but no patent) for Shionogi S-217622 but blinding (neither paper nor patent) of SH-879 from Sosei Heptares. Challenges of extracting and mapping chemical structures between papers and patents for M-Prot lead inhibitors will be outlined
Files
Files
(3.1 MB)
| Name | Size | |
|---|---|---|
|
md5:13cebe5bbd90bda956432b138f2a4d47
|
3.1 MB | Download |